Abstract

Dr. Howard A. Pearson (1937–2016) was a pioneering figure in pediatric hematology whose work significantly advanced the understanding, diagnosis, and management of childhood blood disorders. His landmark contributions include foundational research on sickle cell disease, refinements in diagnostic approaches to aplastic anemia, and the original description of Pearson Marrow Pancreas Syndrome, a rare mitochondrial cytopathy now recognized worldwide. Through his scientific leadership, editorial stewardship of Pediatric Research, and mentorship of generations of clinicians, Pearson played a central role in shaping modern pediatric hematology. His work laid the basis for newborn screening programs, improved survival in hemoglobinopathies, and expanded the conceptual framework of pediatric marrow failure syndromes. This paper summarizes the clinical, scientific, and educational legacy of Dr. Howard A. Pearson and highlights his enduring impact on child health. Key Messages: Howard A. Pearson was a leading architect of modern pediatric hematology, especially in the fields of sickle cell disease and bone marrow failure. He first described Pearson Marrow–Pancreas Syndrome, a pivotal discovery that expanded the understanding of mitochondrial diseases in children. His work contributed to the establishment of newborn screening and early prophylactic strategies for sickle cell disease, reducing childhood mortality. Pearson advanced diagnostic and clinical approaches for aplastic anemia and marrow failure, influencing current therapeutic pathways. As Editor-in-Chief of Pediatric Research and president of ASPHO, he shaped pediatric scientific communication and professional standards. His mentorship and advocacy for children created a long-lasting educational and clinical legacy, impacting generations of pediatricians worldwide.

• 1.   Pearson H.A. History of pediatric hematology oncology. Pediatr Res. 2002; 52(6): 979–992. doi:10.1203/00006450-200212000-00026.
• 2.   Pearson H.A. Neonatal hematology: A historical overview. In: de Alarcón P.A., Werner E.J., editors. Neonatal Hematology: Pathogenesis, Diagnosis, and Management of Hematologic Problems. Cambridge: Cambridge University Press; 2009. pp. 1–9. doi:10.1017/CBO9780511545306.003.
• 3.   Heath H.W., Pearson H.A. Thrombocytosis in pediatric outpatients. J Pediatr. 1989; 114(5): 805– 807. doi:10.1016/S0022-3476(89)80141-6.
• 4.   Pearson H.A. (In) Neonatal Hematology — historical chapter reprint in 3rd edition. In: de Alarcón P.A., Werner E.J., Christensen RD, editors. Neonatal Hematology. 3rd ed.
• 5.   Pearson H.A. (In) Oski F.A., Naiman J.L., editors. Hematologic Problems of the Newborn. Philadelphia: W.B. Saunders; 1966. (Contribution by Howard A. Pearson in historical context referenced in later editions).
• 6.   Pearson H.A. (Acceptance) American Pediatric Society John Howland Award 2002: acceptance. Pediatr Res. 2003; 53(3): 529–532. PMID:12595608.
• 7.   Pearson H.A. (Chapter contribution referenced in broader literature) Routine screening of umbilical cord blood for sickle cell diseases. J Am Med Assoc. 1974; 227(4): 420–422. (Historic contribution cited in neonatal hematology reviews).

Data Sharing Statement

Funding